

GILEAD SCIENCES INC  
Form 3  
May 31, 2016

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

YOUNG KEVIN  
(Last) (First) (Middle)

333 LAKESIDE DRIVE  
(Street)

FOSTER CITY, CA 94404  
(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)  
05/24/2016

3. Issuer Name and Ticker or Trading Symbol  
GILEAD SCIENCES INC [GILD]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer ☐ Other  
(give title below) (specify below)  
Chief Operating Officer

5. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

Common Stock

2. Amount of Securities Beneficially Owned  
(Instr. 4)

1,126

3. Ownership Form:  
Direct (D)  
or Indirect (I)  
(Instr. 5)

D

4. Nature of Indirect Beneficial Ownership  
(Instr. 5)

A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and Expiration Date  
(Month/Day/Year)

Date Exercisable      Expiration Date

3. Title and Amount of Securities Underlying Derivative Security  
(Instr. 4)

Title      Amount or Number of

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security:  
Direct (D)  
or Indirect

6. Nature of Indirect Beneficial Ownership  
(Instr. 5)

# Edgar Filing: GILEAD SCIENCES INC - Form 3

|                                           |              |            |              | Shares |               | (I)<br>(Instr. 5) |   |
|-------------------------------------------|--------------|------------|--------------|--------|---------------|-------------------|---|
| Non-qualified Stock Option (Right to Buy) | Â <u>(1)</u> | 02/01/2023 | Common Stock | 27,118 | \$ 40.56      | D                 | Â |
| Non-qualified Stock Option (Right to Buy) | Â <u>(1)</u> | 02/01/2024 | Common Stock | 4,641  | \$ 80.65      | D                 | Â |
| Non-qualified Stock Option (Right to Buy) | Â <u>(1)</u> | 02/10/2025 | Common Stock | 6,820  | \$ 98.32      | D                 | Â |
| Non-qualified Stock Option (Right to Buy) | Â <u>(1)</u> | 02/10/2026 | Common Stock | 7,715  | \$ 87.8       | D                 | Â |
| Restricted Stock Unit                     | Â <u>(2)</u> | 02/10/2026 | Common Stock | 8,060  | \$ <u>(3)</u> | D                 | Â |

## Reporting Owners

| Reporting Owner Name / Address                               | Relationships |           |                           |       |
|--------------------------------------------------------------|---------------|-----------|---------------------------|-------|
|                                                              | Director      | 10% Owner | Officer                   | Other |
| YOUNG KEVIN<br>333 LAKESIDE DRIVE<br>FOSTER CITY,Â CAÂ 94404 | Â             | Â         | Â Chief Operating Officer | Â     |

## Signatures

/s/ Kevin Young                      05/31/2016  
 \*\*Signature of                      Date  
 Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- (2) The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
- (3) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.